The Confirmation study TA-AAb panel plus AFP was significantly better at distinguishing HCC from NCCLD samples than the TA-AAb panel (p<0.0001) or AFP (p = 0.0122) alone. The gene discussed is AFP; the disease is hepatocellular carcinoma.